Study #2022-0870
A phase IIIb, single-Arm, multicenter study to assess efficacy, safety, and tolerability of Ropeginterferon alfa-2b-njft (P1101) in adult patients with Polycythemia Vera (PV)
MD Anderson Study Status
Not Accepting
Treatment Agent
P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
Description
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Polycythemia Vera
Study phase:
Phase III
Physician name:
Lucia Masarova
Department:
Leukemia
For general questions about clinical trials:
1-855-799-3642
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.